| The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells WJ Harris, X Huang, JT Lynch, GJ Spencer, JR Hitchin, Y Li, F Ciceri, ... Cancer cell 21 (4), 473-487, 2012 | 641 | 2012 |
| Therapeutic antibodies—the coming of age WJ Harris, S Emery Trends in biotechnology 11 (2), 42-44, 1993 | 176 | 1993 |
| Enhancer activation by pharmacologic displacement of LSD1 from GFI1 induces differentiation in acute myeloid leukemia A Maiques-Diaz, GJ Spencer, JT Lynch, F Ciceri, EL Williams, ... Cell reports 22 (13), 3641-3659, 2018 | 174 | 2018 |
| LSD1 inhibition: a therapeutic strategy in cancer? JT Lynch, WJ Harris, TCP Somervaille Expert opinion on therapeutic targets 16 (12), 1239-1249, 2012 | 149 | 2012 |
| Tibtech Feb. 1993 vol. 11 WJ Harris, WJ Harris Therapeutic antibodies--the coming of age, 42-44, 0 | 32 | |
| Pharmacological inhibitors of LSD1 promote differentiation of myeloid leukemia cells through a mechanism independent of histone demethylation JT Lynch, GJ Spencer, WJ Harris, A Maiques-Díaz, F Ciceri, X Huang, ... Blood 124 (21), 267, 2014 | 10 | 2014 |
| Strategies for humanizing antibodies SC Emery, WJ Harris Antibody Engineering 2, 159-183, 1995 | 10 | 1995 |
| Pharmacological inhibition or genetic knockdown of Kdm1a (Lsd1 or Aof2) induces differentiation of MLL acute myeloid leukaemia stem cells WJ Harris, X Huang, JT Lynch, T Somervaille Blood 118 (21), 58, 2011 | 3 | 2011 |
| The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukaemia stem cells WJ Harris PQDT-Global, 2013 | | 2013 |
| LSD1 WJ Harris | | |
Allan JordanVice President of Oncology Drug Discovery, Sygnature DiscoveryE-mail megerősítve itt: thejordans.org.uk
